Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma

Zhang, Xuelin; Xu, Yunhua; Chun-ya, HE; Guo, Xiaowei; Zhang, Jian; He, Chengzhi; Zhang, Ling; Kong, Min; Chen, Baofu; Zhu, Chengchu

doi:10.1002/jso.23888

Cited by 92 publications

(79 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many recent studies have shown that abnormal expression of lncRNA may be found in many types of cancer [11,13]. The formation and progress of esophageal cancer is a complicated, multistep, and progressive process that involves the regulatory effects of multiple genes.…”

Section: Discussionmentioning

confidence: 99%

“…For instance, H19 was the first lncRNA associated with cancer, which is upregulated in many types of human cancer, such as liver cancer, bladder cancer, and breast cancer, and functions as an oncogene [6,7]. Some tumor-related lncRNAs are also capable of serving as potential markers, and dysregulation of their expression is often related to the clinicopathological features and even prognosis of patients [8][9][10][11]. For example, MALAT-1 enhances the cell motility of lung adenocarcinoma and is treated as a specific marker of non-small cell lung cancer, especially in the early metastasis stage of lung adenocarcinoma [9].…”

mentioning

confidence: 99%

See 1 more Smart Citation

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Jiang

Wang

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Jiang

Wang

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…Multiple types of lncRNA have been identified as associated with the development and progression of ESCC, including pist, colon cancer-associated transcript 2, homeobox transcript antisense RNA and metastasis-associated lung adenocarcinoma transcript 1 (26)(27)(28)(29)(30)(31). SBF2-AS1 is a novel lncRNA transcribed on chromosome 11p15.1 and, previously, its function and molecular mechanism in NSCLC has been reported (14).…”

Section: Discussionmentioning

confidence: 99%

Upregulated long non-coding RNA SBF2-AS1 promotes proliferation in esophageal squamous cell carcinoma

et al. 2018

View full text Add to dashboard Cite

Abstract. Esophageal cancer is one of the most common types of malignant tumors located within the digestive system, with >50% of esophageal cancer cases worldwide occurring in China. Recent studies have demonstrated that long non-coding RNAs (lncRNAs) are frequently dysregulated in cancer; however, few lncRNAs have been characterized in esophageal squamous cell carcinoma (ESCC). In the present study, a novel lncRNA, SET-binding factor 2 (SBF2) antisense RNA1 (SBF2-AS1) was exhibited in ESCC. Expression levels of SBF2-AS1 in ESCC and adjacent non-cancerous tissues were detected using the reverse transcription-quantitative polymerase chain reaction. SBF2-AS1 was knocked down, and proliferation, migration, invasion, apoptosis and the cell cycle were examined in ESCC cells. Results identified that SBF2-AS1 was significantly upregulated in ESCC compared with adjacent non-cancerous tissues (fold increase, 8.82; P= 0.023). The SBF2-AS1 expression level was significantly increased in patients who had a smoking (9.927 vs. 4.507; P=0.030) and/or drinking (10.938 vs. 4.232; P=0.032) history. Patients with a large tumor size exhibited increased SBF2-AS1 expression (≥4 vs. <4 cm, 14.898 vs. 5.435; P=0.018). Patients with advanced ESCC exhibited increased upregulation of SBF2-AS1 [tumor-node-metastasis (TNM) I-II vs. TNM III-IV, 1.302 vs. 15.475; P<0.01]. SBF2-AS1 was also silenced using small interfering RNA. Cell proliferative and invasive ability were significantly inhibited (P<0.05) following SBF2-AS1 silencing, the cell cycle was arrested in the G 2 phase; however, there was no significant difference in the proportion of apoptotic cells. Gene Set Enrichment Analysis revealed that genes associated with cell cycle biological processes, including the cancer suppressor gene cyclin-dependent kinase 1A (CDKN1A), were significantly associated with SBF2-AS1 in ESCC tissues. Further validation confirmed that CDKN1A expression levels were increased in ECA-109 cells following SBF2-AS1 silencing. The results of the present study demonstrate that SBF2-AS1 is significantly upregulated in ESCC, and that silencing of SBF2-AS1 inhibits the proliferative and invasive ability of ESCC cells. SBF2-AS1 may be a novel biomarker and therefore a potential therapeutic target for ESCC. IntroductionHuman esophageal cancer (EC) is the third most common digestive system malignancy worldwide, and is associated with a high mortality rate (1). EC is also one of the most common malignant tumors in China, ranking third and Abbreviations: ESCC, esophageal squamous cell carcinoma; EA, esopha geal adenocarcinoma; ncRNA, non-coding RNA; lncRNA, long non-coding RNA; SBF2-AS1, SET-binding factor 2 antisense RNA 1; CCK-8, Cell Counting Kit-8; PRC2, Polycomb repressive complex 2; CDKN1A, cyclin-dependent kinase inhibitor 1A

show abstract

“…Levels of linc-POU3F3 are increased in ESCC samples from patients compared with noncancerous tissues [ 104 ]. Elevated expression of lncRNA CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma [ 105 ].…”

Section: Lncrnas and The Esophagusmentioning

confidence: 99%

Noncoding RNAs in Cancer Diagnosis

Zeng

2016

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

The accuracy and efficiency of tumor treatment depends mainly on early and precise diagnosis. Although histopathology is always the gold standard for cancer diagnosis, noninvasive biomarkers represent an opportunity for early detection and molecular staging of cancer. Besides the classical tumor markers, noncoding RNAs (ncRNAs) emerge to be a novel category of biomarker for cancer diagnosis since the dysregulation of ncRNAs is closely associated with the development and progression of human cancers such as liver, lung, breast, gastric, and other kinds of cancers. In this chapter, we will summarize the different types of ncRNAs in the diagnosis of major human cancers. In addition, we will introduce the recent advances in the detection and applications of circulating serum or plasma ncRNAs and non-blood fluid ncRNAs because the noninvasive body fluid-based assays are easy to examine for cancer diagnosis and monitoring.

show abstract

Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma

Abstract: Our study provides the first evidence associating CCAT2 expression and poor survival in ESCC. CCAT2 may be a prognostic biomarker and therapeutic target for ESCC.

Cited by 92 publications

References 31 publications

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

High TUG1 expression is associated with chemotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Upregulated long non-coding RNA SBF2-AS1 promotes proliferation in esophageal squamous cell carcinoma

Noncoding RNAs in Cancer Diagnosis

Contact Info

Product

Resources

About